Arthur Clements

1.3k total citations
21 papers, 996 citations indexed

About

Arthur Clements is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Arthur Clements has authored 21 papers receiving a total of 996 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 12 papers in Molecular Biology and 3 papers in Epidemiology. Recurrent topics in Arthur Clements's work include Melanoma and MAPK Pathways (12 papers), Cutaneous Melanoma Detection and Management (10 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Arthur Clements is often cited by papers focused on Melanoma and MAPK Pathways (12 papers), Cutaneous Melanoma Detection and Management (10 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Arthur Clements collaborates with scholars based in Australia, United States and Chile. Arthur Clements's co-authors include Richard Kefford, Georgina V. Long, Rachael Anforth, Pablo Fernández‐Peñas, Alexander M. Menzies, Matteo S. Carlino, Giuliana Carlos, Shaun Chou, Bo Gao and Bavanthi Balakrishnar and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and European Journal of Cancer.

In The Last Decade

Arthur Clements

21 papers receiving 981 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arthur Clements Australia 16 704 559 128 110 105 21 996
Kiran Patel United States 14 814 1.2× 920 1.6× 131 1.0× 160 1.5× 54 0.5× 37 1.4k
G. S. Falchook United States 13 411 0.6× 516 0.9× 108 0.8× 176 1.6× 80 0.8× 31 753
Yanmei Xu China 9 528 0.8× 736 1.3× 143 1.1× 121 1.1× 53 0.5× 21 1.0k
Laure A Moutouh-de Parseval United States 6 790 1.1× 922 1.6× 136 1.1× 140 1.3× 198 1.9× 7 1.3k
Sònia Pernas Spain 20 1.1k 1.6× 413 0.7× 447 3.5× 129 1.2× 130 1.2× 109 1.6k
Kilannin Krysiak United States 13 240 0.3× 371 0.7× 64 0.5× 228 2.1× 126 1.2× 26 794
Uwe Fraass Germany 6 709 1.0× 589 1.1× 169 1.3× 27 0.2× 124 1.2× 13 1.1k
Jeffrey Skolnik United States 17 518 0.7× 554 1.0× 126 1.0× 198 1.8× 146 1.4× 32 1.2k
Ivana Krajsová Czechia 16 1.4k 2.1× 1.5k 2.7× 213 1.7× 199 1.8× 49 0.5× 40 1.9k
Maryann Redlinger United States 14 525 0.7× 459 0.8× 193 1.5× 79 0.7× 43 0.4× 25 1.1k

Countries citing papers authored by Arthur Clements

Since Specialization
Citations

This map shows the geographic impact of Arthur Clements's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arthur Clements with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arthur Clements more than expected).

Fields of papers citing papers by Arthur Clements

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arthur Clements. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arthur Clements. The network helps show where Arthur Clements may publish in the future.

Co-authorship network of co-authors of Arthur Clements

This figure shows the co-authorship network connecting the top 25 collaborators of Arthur Clements. A scholar is included among the top collaborators of Arthur Clements based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arthur Clements. Arthur Clements is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Wei, Jessica L. Smith, Matteo S. Carlino, et al.. (2021). Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma. Clinical and Translational Radiation Oncology. 30. 95–99. 7 indexed citations
2.
Lee, Jenny, Megan Lyle, Alexander M. Menzies, et al.. (2017). Metastasis‐specific patterns of response and progression with anti‐PD‐1 treatment in metastatic melanoma. Pigment Cell & Melanoma Research. 31(3). 404–410. 35 indexed citations
3.
Carlos, Giuliana, Rachael Anforth, Shaun Chou, Arthur Clements, & Pablo Fernández‐Peñas. (2015). A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Research. 25(3). 265–268. 97 indexed citations
4.
Carlos, Giuliana, Rachael Anforth, Arthur Clements, et al.. (2015). Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. JAMA Dermatology. 151(10). 1103–1103. 107 indexed citations
5.
Anforth, Rachael, Giuliana Carlos, Noemí Eirís, Arthur Clements, & Pablo Fernández‐Peñas. (2015). Tinea hidden by a vemurafenib‐induced phototoxic reaction in a patient with metastatic melanoma taking dexamethasone. The Medical Journal of Australia. 203(1). 41–42. 2 indexed citations
6.
Lam, Teresa, Matthew Chan, Arianne Sweeting, et al.. (2015). Ipilimumab‐induced hypophysitis in melanoma patients: an Australian case series. Internal Medicine Journal. 45(10). 1066–1073. 25 indexed citations
7.
Menzies, Alexander M., Lauren E. Haydu, Mary Azer, et al.. (2014). Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. Melanoma Research. 24(5). 468–474. 31 indexed citations
8.
Anforth, Rachael, Giuliana Carlos, Arthur Clements, Richard Kefford, & Pablo Fernández‐Peñas. (2014). Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks. British Journal of Dermatology. 172(1). 239–243. 33 indexed citations
9.
Lyle, Megan, Jenny Lee, Alexander M. Menzies, et al.. (2014). Lesion-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma (MM).. Journal of Clinical Oncology. 32(15_suppl). 9077–9077. 19 indexed citations
10.
Chan, Matthew, Richard Kefford, Matteo S. Carlino, Arthur Clements, & Nicholas Manolios. (2014). Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma. Journal of Immunotherapy. 38(1). 37–39. 96 indexed citations
11.
Hong, Angela, Arthur Clements, Dion Forstner, et al.. (2014). Acute Radiation Skin Toxicity Associated With BRAF Inhibitors. Journal of Clinical Oncology. 34(3). e17–e20. 16 indexed citations
12.
Chan, Matthew, Lauren E. Haydu, Alexander M. Menzies, et al.. (2014). The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition. Cancer. 120(20). 3142–3153. 56 indexed citations
13.
Anforth, Rachael, Michael Liu, Bao N. Nguyen, et al.. (2013). Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib. Australasian Journal of Dermatology. 55(4). 250–254. 63 indexed citations
14.
Anforth, Rachael, Tatiana Cristina Moraes Pinto Blumetti, Arthur Clements, et al.. (2013). Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. British Journal of Dermatology. 169(6). 1310–1313. 31 indexed citations
15.
Klein, Oliver, Antoni Ribas, Bartosz Chmielowski, et al.. (2013). Facial Palsy As a Side Effect of Vemurafenib Treatment in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 31(12). e215–e217. 24 indexed citations
16.
Klein, Oliver, Arthur Clements, Alexander M. Menzies, et al.. (2012). BRAF inhibitor activity in V600R metastatic melanoma. European Journal of Cancer. 49(5). 1073–1079. 89 indexed citations
17.
Menzies, Alexander M., et al.. (2012). Correlates of fever in patients (pts) receiving combined dabrafenib (GSK2118436) plus trametinib (GSK1120212) for V600 BRAF-mutant metastatic melanoma (MM).. Journal of Clinical Oncology. 30(15_suppl). e19011–e19011. 2 indexed citations
18.
Gao, Bo, et al.. (2012). Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies. Journal of Clinical Oncology. 30(32). 4017–4025. 158 indexed citations
19.
Infante, J. R., G. S. Falchook, Donald P. Lawrence, et al.. (2011). Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).. Journal of Clinical Oncology. 29(18_suppl). CRA8503–CRA8503. 101 indexed citations
20.
Clements, Arthur & M. C. Jones. (1991). An ecological example of the application of projection pursuit to compositional data. Vegetatio. 95(2). 101–107. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kiran Patel Breakdown of academic impact, for papers by G. S. Falchook Breakdown of academic impact, for papers by Yanmei Xu Breakdown of academic impact, for papers by Laure A Moutouh-de Parseval Breakdown of academic impact, for papers by Sònia Pernas Breakdown of academic impact, for papers by Kilannin Krysiak Breakdown of academic impact, for papers by Uwe Fraass Breakdown of academic impact, for papers by Jeffrey Skolnik Breakdown of academic impact, for papers by Ivana Krajsová Breakdown of academic impact, for papers by Maryann Redlinger
Rankless by CCL
2026